Omnigraf is a trade mark of Transplant Genomics, the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide. The breakthrough in assessing kidney rejection is expected to strengthen the overall outcomes for kidney transplant patients.

Omnigraf combines the Trugraf blood gene expression test and Viracor Trac donor-derived cell-free DNA assays. According to the press release by Eurofins, combining genetic biomarkers does not only allow for better prediction with the highest positive predictive value and negative predictive value available in a diagnostic panel, but Ominigraf will also be the first diagnostic tool that combines cell free DNA and gene expression data to derive its results. This innovation is made possible thanks to collaborative efforts with the Northwestern University.

“We are very pleased to have collaborated with Northwestern University on this highly innovative test which will facilitate speed and accuracy in rejection detection, and, critically, improve patient outcomes. This partnership highlights the Group’s commitment to innovation and the advancement of science to improve the health and safety of our world. We look forward to the roll out of this test to medical institutions globally, so transplant patients and healthcare professionals can benefit from strengthened insights to inform treatment decisions,” said Eurofins CEO, Dr. Gilles Martin

Omnigraf requires 6 milliliters (mL) of blood, which can be obtained via routine sampling, which in turn simplifies sample collection and logistics.

Dr. John Friedewald from Northwestern University said the revolutionary test “allows transplant centers, the community of nephrologists, and transplant patients to make informed and more frequent decisions about managing immunosuppression and kidney transplant health.  I see this as a major advance in enhancing patient care and bringing hope and peace of mind to our patients.”